Name: Proteomics International Laboratories (PIQ) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

PIQ

Pharmaceuticals, Biotechnology & Life Sciences

Proteomics International Laboratories

Short interest: 0.36%; −0.29 pp 30d; as of 8 Oct 2026
Reported shorts: 587.3K
Shares on issue: 165.373M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Proteomics International Laboratories

Proteomics International Laboratories Ltd (ASX:PIQ) is a medical technology company specializing in predictive diagnostics and bio-analytical services. They focus on proteomics, the industrial-scale study of protein structure and function, to develop novel diagnostic tests like PromarkerD, PromarkerEndo, and PromarkerEso, aiming to bring these to global markets.

Company profile →

Proteomics International Laboratories (ASX:PIQ) has 0.36% of its shares on issue reported as short positions as of 8 Oct 2026, or about 587,286 shares. Over the past 30 days that figure has fallen 0.29 percentage points, and over 90 days it has fallen 0.18 percentage points. Its highest recorded short interest was 0.71% in August 2026. PIQ is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads PIQ today

Zanger BreakoutWatchScore 25rank 988 of 1931
CAN SLIMWatchScore 10rank 1113 of 1541
Minervini Trend TemplateWatchScore 6rank 1644 of 1736
Crowded-Short BreakoutWatchScore 10rank 993 of 1479
Quality compoundersWatchScore 10rank 1271 of 1677

Prices to 13 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

PIQ fundamentals

In the year to 30 Jun 2026, Proteomics International Laboratories (ASX:PIQ) recorded revenue of A$3.4M and a net loss after tax of A$8.6M. A year earlier it recorded revenue of A$960.4K and a net loss after tax of A$8.1M. Year-on-year growth: revenue +250.9% (FY). Net margin −254.0% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →